AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kezar Life Sciences Q2 Earnings Exceed Expectations, Cash Reserves Down
ByAinvest
Wednesday, Aug 13, 2025 4:37 pm ET1min read
Kezar Life Sciences reported Q2 GAAP EPS of -$1.87, beating estimates by $0.42. Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024, primarily due to cash used in operations.
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases, has reported its financial results for the second quarter of 2025. The company's GAAP EPS of -$1.87 beat estimates by $0.42, according to a press release issued on July 2, 2025.The company's cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024. This decrease was primarily due to cash used in operations. The company also reported a net loss of $13.7 million for the second quarter, compared to a net loss of $21.5 million for the same period in 2024.
Research and development (R&D) expenses decreased by $6.7 million to $9.6 million in the second quarter of 2025, primarily due to the completion and closeout of clinical trials, a decrease in personnel costs, and a decrease in facility-related expenses. General and administrative (G&A) expenses also decreased by $0.6 million to $5.0 million, primarily due to a decrease in non-cash stock-based compensation and personnel-related expenses.
Zetomipzomib, a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis, remains a key focus for Kezar Life Sciences. The company is committed to working closely with the FDA to align on the next trial design for zetomipzomib, which is proposed as a registration-enabling study. The company also announced the promotion of Zung To to Chief Development Officer, who brings 35 years of industry experience to the role.
For more information, visit [Kezar Life Sciences](https://www.kezarlifesciences.com).
References:
[1] https://www.marketscreener.com/news/kezar-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-update-ce7c51d8d889f123
[2] https://seekingalpha.com/news/4484964-kezar-life-sciences-gaap-eps-of-1_87-beats-by-0_42
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet